FASN and metabolic dysfunction-associated steatohepatitis: The upregulated SHP exerted an inhibitory impact on LXRα and, successively, on FASN expression (NASH vs. NASH + 100 mg/kg γ-MCA, p = 0.0213 in the transcriptional level, p = 0.0003 in the translational level; NASH + 10 mg/kg γ-MCA vs. NASH + 100 mg/kg γ-MCA, p = 0.0410 in the transcriptional level, p = 0.0168 in the translational level) (Figure 6A–C).